Saturday, October 27, 2012

Vertex To Release Q3 2012 Hep C Revenue Data Monday

FINAL UPDATE | 11.01.12:

Vertex reports that (as I predicted) 75 percent of all new Hep C current-gen patients — some $254 million worth in Q3 2012, alone — are receiveing Incivek, over Victrelis (New Merck/legacy Schering-Plough). However, it seems many of the less severely afflicted Hep C positive patients are waiting — deferring any treatment — for the arrival of the all-oral next-gen Hep C “cures” now in Phase II/III clinical trials.

UPDATED: Call now moved to November 1, 2012, due to Sandy.

Next up, on Thursday Monday evening, Vertex Pharmaceuticals reports its third quarter revenue from telaprevir, branded as Incivek. I expect at least a 75-25 advantage in market share, for Vertex, over the rival Merck (actually, legacy Schering-Plough) drug, boceprevir.

But we shall see. You may tune in here:
. . . .As a result of the effects of Hurricane Sandy and the related closure of the financial markets, Vertex Pharmaceuticals Incorporated today announced that it has rescheduled its third quarter 2012 earnings press release and conference call, which were originally scheduled for today, Monday, October 29. Vertex will now announce its third quarter 2012 financial results on Thursday, November 1, 2012 after the financial markets close. The company will host a conference call at 5:00 p.m. EDT on Thursday. . . .

. . .Oct 29, 2012 | 5:00 PM ET
Vertex Pharmaceuticals Incorporated Third Quarter 2012 Financial Results Conference Call.  . . .
We will report on it, then. As ever, be careful out there.


Anonymous said...

just a bit off topic but, I am disappointed~~no 'Get out and Vote' notice on the blog?!

So, unlike you.

Condor said...

Seems I was a little too busy this year -- on the ground in Iowa -- and elsewhere.

Ah, so it goes.

All's well that ends well, right.

See you in DC on January 21, 2013.